Amarin buyout rumor































Yes of course, EVERYONE is interested in a 30 year old Japanese fish-oil that aren't economically viable, who has no real patents and that everyone can sell otc today if they want to:)

Desperate Amarin has been looking for a partner for several years now, long before they started the trials even..

It's a scam people.
 






Yes of course, EVERYONE is interested in a 30 year old Japanese fish-oil that aren't economically viable, who has no real patents and that everyone can sell otc today if they want to:)

Desperate Amarin has been looking for a partner for several years now, long before they started the trials even..

It's a scam people.


I don't trust the opinion of someone who doesn't use correct grammar.
 




































Tards,all of you, except the last poster, you are a turd. We don't need top buy anyone. Just cut us like you did everyone else.

Cut me Mick, cut me.....name, u, duh, the movie
 






The deal is already in the works. Why do you think Amarin cancelled their presentation at the UBS conference today?

The main reason was probably the bad press, that fishoil is useless to prevent cardiovascular diseases. In Europe, the cardiologists have already recently changed the guidelines, saying that there is not enough evidence to recommend regularly use of Omega-3. In addition, recent US guideline regarding highly elevated triglycerides recommend fenofibrate as first line treatment, that is already available as cheap generics. It seems, that the positive impact of fish consumption (still recommend by European cardiologists) is not just due to Omega-3, but other ingredients, like parathormon like peptides or phospholipides. E.g., there is a French product made of salmon heads being more effective in reducing dyslipidemia, but contain only 1/50 of a typical fish oil capsule - the product is called Vectomega. An Israelian company has developed a dervative of the bad LDL Cholesterin being effective in micro gramm dosages orally against metabolic syndrome.

Nevertheless, with big marketing pockets Vascepa might become a blockbuster like recently introduced Vascazen by Pivotal therapeutics....
 






The main reason was probably the bad press, that fishoil is useless to prevent cardiovascular diseases. In Europe, the cardiologists have already recently changed the guidelines, saying that there is not enough evidence to recommend regularly use of Omega-3. In addition, recent US guideline regarding highly elevated triglycerides recommend fenofibrate as first line treatment, that is already available as cheap generics. It seems, that the positive impact of fish consumption (still recommend by European cardiologists) is not just due to Omega-3, but other ingredients, like parathormon like peptides or phospholipides. E.g., there is a French product made of salmon heads being more effective in reducing dyslipidemia, but contain only 1/50 of a typical fish oil capsule - the product is called Vectomega. An Israelian company has developed a dervative of the bad LDL Cholesterin being effective in micro gramm dosages orally against metabolic syndrome.

Nevertheless, with big marketing pockets Vascepa might become a blockbuster like recently introduced Vascazen by Pivotal therapeutics....

missed the link http://jama.jamanetwork.com/article.aspx?articleid=1357266
 












The main reason was probably the bad press, that fishoil is useless to prevent cardiovascular diseases. In Europe, the cardiologists have already recently changed the guidelines, saying that there is not enough evidence to recommend regularly use of Omega-3. In addition, recent US guideline regarding highly elevated triglycerides recommend fenofibrate as first line treatment, that is already available as cheap generics. It seems, that the positive impact of fish consumption (still recommend by European cardiologists) is not just due to Omega-3, but other ingredients, like parathormon like peptides or phospholipides. E.g., there is a French product made of salmon heads being more effective in reducing dyslipidemia, but contain only 1/50 of a typical fish oil capsule - the product is called Vectomega. An Israelian company has developed a dervative of the bad LDL Cholesterin being effective in micro gramm dosages orally against metabolic syndrome.

Nevertheless, with big marketing pockets Vascepa might become a blockbuster like recently introduced Vascazen by Pivotal therapeutics....

Thanks for your convaluted bullshit. If you truly understood the market it would have helped you to misguide people much more convincingly. Since I have been on Lovaza for quite some time and called on Cardiologists for years, I will tell you that if you use a therapeutic dose and use the proper rate of significance (and prospective studies insted of the old meta analysis game) to judge you might be in a different place today. My cardiologists said he was on variuos chats with his colleagues, all lipidologists and they all laughed at the Greece study. Thats for what its worth. The fibrates, yeah they are great, ever take them? I have. Whatever and who cares. I just want Eliquis in my bag.
 






I agree to a certain extent. To say fish oil is useless in preventing cardiac events is incorrect since there are no outcome studies to prove this or not. I am intrigued by what I read of these products but it looks like the doses need to be above 3grams at least to be effective for patients with high tg. The supplements on the shelves at the pharmacies are just plain grotesque. This new one may be a winner, but we will have to wait and see. I just wish we would get back into cardiology. Get us a new product already!
 












Thanks for your convaluted bullshit. If you truly understood the market it would have helped you to misguide people much more convincingly. Since I have been on Lovaza for quite some time and called on Cardiologists for years, I will tell you that if you use a therapeutic dose and use the proper rate of significance (and prospective studies insted of the old meta analysis game) to judge you might be in a different place today. My cardiologists said he was on variuos chats with his colleagues, all lipidologists and they all laughed at the Greece study. Thats for what its worth. The fibrates, yeah they are great, ever take them? I have. Whatever and who cares. I just want Eliquis in my bag.

Unfortunatley, especially the outcome studies using LOVAZA had the negative impact on the metaanalysis - just to mention the following studies OMEGA (Senges et al.), ORIGIN (Bosch et al.) and last but not least the GSK sponsored atrial fibrillation trial (Kowey et al.)